Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Gliatech (GLIA) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (1163)	1/8/2000 8:40:00 PM
From: M. P. McNamara, Jr. M.D.	Read Replies (1) \| Respond to of 2001

Rick-- Perhaps I was a bit opaque with post 1142. Then again, neither one of us would have to post about awarded patents if the company would issue timely press releases about it's intellectual properties and progress.

To: scaram(o)uche who wrote (1163)	1/11/2000 1:02:00 AM
From: scaram(o)uche	Read Replies (4) \| Respond to of 2001

Bizarre presentation....... No mention of FDA import halt, therefore no mention of whether or not the pipe is being filled. Sales presented through third quarter, didn't even mention that a hit is coming for Q4. No discussion of either strategy or ongoing negotiations, Perceptin licensing. No mention of LCBM and competitive position relative to hyaluronate-derived product candidates. No mention of Janssen. No mention of reimbursement issues. Adcon-L has now been administered to over 100,000 patients. They see it as over a $200 million/year opportunity. "A safe product." Current penetration 14 1/2%. Excellent reorder rate, "virtually 100% of hospitals that have ordered the product have reordered." Adcon-T/N..... available in 28 countries, CE mark in EU. Pivotal trials in U.S. Targeting a "regulatory submission". Adcon-P/A..... proprietary resorbable liquid. Prevents surgical and non-surgical adhesions. Good for laparoscopic procedures. Pivotal trial for -P, currently enrolling. Pilot trial for -A, enrollment completed, awaiting patient follow-up. Adcon-I..... breast implants, 300K procedures/year. Capsular contraction is primary complaint in breast implants. Feasibility study underway at six studies, patients enrolling. Acute inflammation..... coronary bypass surgery..... activation of the C' cascade. MAb (anti-properdin) is effective in animal models. He said they have patent protection for the antibody (they do??.... since when?). Currently humanizing. Cognition modulation...... H3 receptor..... he discussed H1R (anti-histamines.... Claritin, etc.). H2 receptor.... Tagamet, etc., for the treatment of ulcers. Sleep disorders, dementia, ADD. Perceptin.... ready to begin phase II clinical trials. Well-tolerated in phase I. Once daily dosing. Schizophrenia..... NMDA glutamate receptor, focused on glycine. Lead compound identified, "building intellectual property estate". Financials discussed through Q3 '99. 2000 objectives..... Approval for -L in Japan (Chugai). Begin U.S. manufacturing for Adcon-L. Regulatory submission for -T/N. File PMA for Adcon-P, and sign distribution agreement. Begin phase II for Perceptin and partner it wit a pharma. Begin pivotal trial, Adcon-A. Complete humanization of anti-properdin. Very poor preparation, IMO. Very little concern for the shareholder, IMO.